A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms

Science Translational Medicine

Volumn 3, Issue 98, 2011, Pages

  Moreno, Jonathan D ^a,b   Zhu, Z Iris ^b   Yang, Pei Chi ^c   Bankston, John R ^d   Jeng, Mao Tsuen ^c   Kang, Chaoyi ^c   Wang, Lianguo ^c   Bayer, Jason D ^e   Christini, David J ^b   Trayanova, Natalia A ^e   Ripplinger, Crystal M ^c   Kass, Robert S ^d   Clancy, Colleen E ^c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; LIDOCAINE; SODIUM CHANNEL;

ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE CONDUCTANCE; CHEMICAL INTERACTION; CHEMICAL REACTION KINETICS; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG POTENCY; ECTOPIA CORDIS; ELECTRIC ACTIVITY; EXPERIMENTAL RABBIT; HEART ARRHYTHMIA; HEART BEAT; HEART ELECTROPHYSIOLOGY; HEART RATE VARIABILITY; HEART RHYTHM; HIDDEN MARKOV MODEL; HUMAN VERSUS NONHUMAN DATA; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; ANIMAL; BIOLOGICAL MODEL; HEART FAILURE; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE; HUMAN; KINETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT; REPRODUCIBILITY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COMPUTER SIMULATION; FLECAINIDE; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART VENTRICLES; HUMANS; KINETICS; LIDOCAINE; MODELS, CARDIOVASCULAR; RABBITS; REPRODUCIBILITY OF RESULTS; SODIUM CHANNELS;

EID: 80052358982     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002588     Document Type: Article

References (55)

1. J. T. Bigger Jr., W. J. Mandel, Effect of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fibers. J. Clin. Invest. 49, 63-77 (1970).
2. M. R. Rosen, B. F. Hoffman, Mechanisms of action of antiarrhythmic drugs. Circ. Res. 32, 1-8 (1973).
3. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. 321, 406-412 (1989).
4. D. S. Echt, P. R. Liebson, L. B.Mitchell, R. W. Peters, D. Obias-Manno, A. H. Barker, D. Arensberg, A. Baker, L. Friedman, H. L. Greene, M. L. Huther, D. W. Richardson; CAST Investigators, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324, 781-788 (1991).
5. A. Burashnikov, C. Antzelevitch, New developments in atrial antiarrhythmic drug therapy. Nat. Rev. Cardiol. 7, 139-148 (2010).
6. C. E. Clancy, Y. Rudy, Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature 400, 566-569 (1999).
7. D. Noble, The rise of computational biology. Nat. Rev. Mol. Cell Biol. 3, 459-463 (2002).
8. B. Rodriguez, K. Burrage, D. Gavaghan, V. Grau, P. Kohl, D. Noble, The systems biology approach to drug development: Application to toxicity assessment of cardiac drugs. Clin. Pharmacol. Ther. 88, 130-134 (2010).
9. L. M. Hondeghem, B. G. Katzung, Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim. Biophys. Acta 472, 373-398 (1977).
10. B. Hille, Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction. J. Gen. Physiol. 69, 497-515 (1977).
11. C. F. Starmer, A. A. Lastra, V. V. Nesterenko, A. O. Grant, Proarrhythmic response to sodiumchannel blockade. Theoretical model and numerical experiments. Circulation 84, 1364-1377 (1991).
12. L. M. Hondeghem, B. G. Katzung, Antiarrhythmic agents: The modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu. Rev. Pharmacol. Toxicol. 24, 387-423 (1984).
13. J. R. Balser, H. B. Nuss, D. W. Orias, D. C. Johns, E. Marban, G. F. Tomaselli, J. H. Lawrence, Local anesthetics as effectors of allosteric gating. Lidocaine effects on inactivation-deficient rat skeletal muscle Na channels. J. Clin. Invest. 98, 2874-2886 (1996).
14. H. L. Greene, D. M. Roden, R. J. Katz, R. L. Woosley, D. M. Salerno, R. W. Henthorn, The Cardiac Arrhythmia Suppression Trial: First CAST ... then CAST-II. J. Am. Coll. Cardiol. 19, 894-898 (1992).
15. D. Colquhoun, K. A. Dowsland, M. Beato, A. J. Plested, How to impose microscopic reversibility in complex reaction mechanisms. Biophys. J. 86, 3510-3518 (2004).
16. L. L. Brunton, J. S. Lazo, K. L. Parker, Goodman & Gilman's The Pharmacological Basis of Therapeutics (McGraw-Hill, New York, ed. 11, 2006).
17. H. Liu, J. Atkins, R. S. Kass, Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: Evidence from experiments with neutral and quaternary flecainide analogues. J. Gen. Physiol. 121, 199-214 (2003).
18. Y. Zhu, J. W. Kyle, P. J. Lee, Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block. Am. J. Physiol. Heart Circ. Physiol. 291, H29-H37 (2006).
19. H. Liu, M. Tateyama, C. E. Clancy, H. Abriel, R. S. Kass, Channel openings are necessary but not sufficient for use-dependent block of cardiac Na+ channels by flecainide: Evidence from the analysis of disease-linked mutations. J. Gen. Physiol. 120, 39-51 (2002).
20. H. Abriel, X. H. Wehrens, J. Benhorin, B. Kerem, R. S. Kass, Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation 102, 921-925 (2000).
21. T. Nagatomo, C. T. January, J. C. Makielski, Preferential block of late sodiumcurrent in the LQT3 DKPQ mutant by the class IC antiarrhythmic flecainide. Mol. Pharmacol. 57, 101-107 (2000).
22. D. T. Yue, J. H. Lawrence, E. Marban, Two molecular transitions influence cardiac sodium channel gating. Science 244, 349-352 (1989).
23. + channels. Modification of block by alterations in the α-subunit III-IV interdomain. Circ. Res. 77, 584-592 (1995).
24. Z. G. Wang, L. C. Pelletier, M. Talajic, S. Nattel, Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 82, 274-283 (1990).
25. E. Ramos, M. E. O'Leary, State-dependent trapping of flecainide in the cardiac sodium channel. J. Physiol. 560, 37-49 (2004).
26. K. H. ten Tusscher, A. V. Panfilov, Alternans and spiral breakup in a human ventricular tissue model. Am. J. Physiol. Heart Circ. Physiol. 291, H1088-H1100 (2006).
27. H. R. Lu, J. Rohrbacher, E. Vlaminckx, K. Van Ammel, G. X. Yan, D. J. Gallacher, Predicting drug-induced slowing of conduction and pro-arrhythmia: Identifying the 'bad' sodium current blockers. Br. J. Pharmacol. 160, 60-76 (2010).
28. S. M. Yabek, R. Kato, N. Ikeda, B. N. Singh, Effects of flecainide on the cellular electrophysiology of neonatal and adult cardiac fibers. Am. Heart J. 113, 70-76 (1987).
29. U. Borchard, M. Boisten, Effect of flecainide on action potentials and alternating current-induced arrhythmias in mammalian myocardium. J. Cardiovasc. Pharmacol. 4, 205-212 (1982).
30. R. M. Shaw, Y. Rudy, Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ. Res. 81, 727-741 (1997).
31. C. F. Starmer, A. A. Lastra, V. V. Nesterenko, A. O. Grant, Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation 84, 1364-1377 (1991).
32. C. Ermis, A. X. Zhu, L. Vanheel, M. J. Lemke, S. Sakaguchi, K. G. Lurie, F. Lu, J. Lin, D. G. Benditt, Comparison of ventricular arrhythmia frequency in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy treated with implantable cardioverter defibrillators. Am. J. Cardiol. 96, 233-238 (2005).
33. C. F. Starmer, How antiarrhythmic drugs increase the rate of sudden cardiac death. Int. J. Bifurcat. Chaos 12, 1953-1968 (2002).
34. G. R. Mines, On circulating excitations in heart muscles and their possible relation to tachycardia and fibrillation. Trans. R. Soc. Can. 4, 43-52 (1914).
35. M. A. Allessie, F. I. Bonke, F. J. Schopman, Circus movement in rabbit atrial muscle as a mechanism of trachycardia. Circ. Res. 33, 54-62 (1973).
36. C. F. Starmer, V. N. Biktashev, D. N. Romashko, M. R. Stepanov, O. N. Makarova, V. I. Krinsky, Vulnerability in an excitable medium: Analytical and numerical studies of initiating unidirectional propagation. Biophys. J. 65, 1775-1787 (1993).
37. M. A. Bray, J. P. Wikswo, Considerations in phase plane analysis for nonstationary reentrant cardiac behavior. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 65, 051902 (2002).
38. A. V. Panfilov, Is heart size a factor in ventricular fibrillation? Or how close are rabbit and human hearts? Heart Rhythm 3, 862-864 (2006).
39. L. Priebe, D. J. Beuckelmann, Simulation study of cellular electric properties in heart failure. Circ. Res. 82, 1206-1223 (1998).
40. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ. Res. 73, 379-385 (1993).
41. A. V. Glukhov, V. V. Fedorov, Q. Lou, V. K. Ravikumar, P. W. Kalish, R. B. Schuessler, N. Moazami, I. R. Efimov, Transmural dispersion of repolarization in failing and nonfailing human ventricle. Circ. Res. 106, 981-991 (2010).
42. Q. Lou, V. V. Fedorov, A. V. Glukhov, N. Moazami, V. G. Fast, I. R. Efimov, Transmural heterogeneity and remodeling of ventricular excitation-contraction coupling in human heart failure. Circulation 123, 1881-1890 (2011).
43. S. Rohr, J. P. Kucera, A. G. Kléber, Slow conduction in cardiac tissue, I: Effects of a reduction of excitability versus a reduction of electrical coupling on microconduction. Circ. Res. 83, 781-794 (1998).
44. Y. Wang, Y. Rudy, Action potential propagation in inhomogeneous cardiac tissue: Safety factor considerations and ionic mechanism. Am. J. Physiol. Heart Circ. Physiol. 278, H1019-H1029 (2000).
45. T. Brennan, M. Fink, B. Rodriguez, Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur. J. Pharm. Sci. 36, 62-77 (2009).
46. F. Marchlinski, The tachyarrhythmias, in Harrison's Principles of Internal Medicine, A. S. Fauci, E. Braunwald, D. L. Kasper, S. L. Hauser, D. L. Longo, J. L. Jameson, J. Loscalzo, Eds. (McGraw-Hill, New York, ed. 17, 2008).
47. L. L. Burton, B. A. Chabner, B. C. Knollan, Goodman & Gilman's The Pharmacological Basis of Therapeutics (McGraw-Hill, New York, ed. 12, 2010).
48. M. T. Slawsky, N. A. Castle, K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J. Pharmacol. Exp. Ther. 269, 66-74 (1994).
49. + current of guinea-pig ventricular myocytes. J. Mol. Cell. Cardiol. 28, 893-903 (1996).
50. F. Scamps, A. Undrovinas, G. Vassort, Inhibition of ICa in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizin. Am. J. Physiol. 256, C549-C559 (1989).
51. Z. Wang, B. Fermini, S. Nattel, Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue. J. Pharmacol. Exp. Ther. 267, 575-581 (1993).
52. T. Yamashita, T. Nakajima, E. Hamada, H. Hazama, M. Omata, Y. Kurachi, Flecainide inhibits the transient outward current in atrial myocytes isolated from the rabbit heart. J. Pharmacol. Exp. Ther. 274, 315-321 (1995).
53. C. H. Follmer, C. A. Cullinan, T. J. Colatsky, Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: Evidence for open channel block and unblock. Cardiovasc. Res. 26, 1121-1130 (1992).
54. S. N. Hatem, A. Coulombe, E. Balse, Specificities of atrial electrophysiology: Clues to a better understanding of cardiac function and the mechanisms of arrhythmias. J. Mol. Cell. Cardiol. 48, 90-95 (2010).
55. Funding: Supported by the American Heart Association (AHA) (grant-in-aid, Western States Affiliate), the Alfred P. Sloan Foundation, and the NIH National Heart, Lung, and Blood Institute (NHLBI) RO1-HL-085592-05 and RO1-HL-085592-S2 (to C.E.C.); NHLBI RO1-HL-56810-16 (to R.S.K.); NHLBI R01-HL-082729 and R01-HL-103428 and National Science Foundation grant CBET- 0933029 (to N.A.T.); NIH P30: HL101280-01 (to C.M.R.); Medical Scientist Training Programgrant 5 T 32 GM 07739 (to J.D.M.); and AHA 10PRE3650037 (to J.D.B.). Author contributions: J.D.M. designed and performed simulations, optimizations, and experiments, and prepared themanuscript; Z.I.Z. designed simulations; P.-C.Y. and M.-T.J. performed optimizations and analysis; J.R.B. and R.S.K. designed and performed experiments; C.K., L.W., and C.M.R. designed, performed, and analyzed optical mapping experiments; J.D.B. and N.A.T. designed and performed 3D modeling; D.J.C. assisted in manuscript preparation; C.E.C. designed simulations and experiments and prepared the manuscript. Competing interests: The authors declare that they have no competing interests.